Biomedical research: increasing value, reducing waste

[1]  David Moher,et al.  Reducing waste from incomplete or unusable reports of biomedical research , 2014, The Lancet.

[2]  Harlan M Krumholz,et al.  Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.

[3]  Iain Chalmers,et al.  How to increase value and reduce waste when research priorities are set , 2014, The Lancet.

[4]  R. Tibshirani,et al.  Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.

[5]  Rustam Al-Shahi Salman,et al.  Increasing value and reducing waste in biomedical research regulation and management , 2014, The Lancet.

[6]  Robert F Terry,et al.  Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory? , 2013, The Lancet.

[7]  John P. A. Ioannidis,et al.  Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review , 2013, European journal of clinical investigation.

[8]  S. Wooding,et al.  The answer is 17 years, what is the question: understanding time lags in translational research , 2011, Journal of the Royal Society of Medicine.

[9]  J. Ross,et al.  Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. , 2011, Archives of internal medicine.

[10]  S. Michie,et al.  The behaviour change wheel: A new method for characterising and designing behaviour change interventions , 2011, Implementation science : IS.

[11]  J. Scadding,et al.  The James Lind Alliance: tackling research mismatches , 2010, The Lancet.

[12]  E. Ringelstein,et al.  Methodological Quality of Preclinical Stroke Studies is Not Required for Publication in High-Impact Journals , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  N. Anderson,et al.  The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. , 2010, Clinical chemistry.

[14]  E Ray Dorsey,et al.  Funding of US biomedical research, 2003-2008. , 2010, JAMA.

[15]  P. Donnan,et al.  A randomised controlled trial of the use of aciclovir and/or prednisolone for the early treatment of Bell's palsy: the BELLS study. , 2009, Health technology assessment.

[16]  P. Glasziou,et al.  Avoidable waste in the production and reporting of research evidence , 2009, The Lancet.

[17]  John P A Ioannidis,et al.  Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.

[18]  Wade S. Smith,et al.  Effect of a US National Institutes of Health programme of clinical trials on public health and costs , 2006, The Lancet.

[19]  G. Barrett,et al.  Research Governance: Regulating Risk and Reducing Harm? , 2006, Journal of the Royal Society of Medicine.

[20]  Michael Marmot,et al.  Social determinants of health inequalities , 2005, The Lancet.

[21]  T. Jefferson,et al.  Peer Review in Health Sciences , 1999 .

[22]  Simon Wessely,et al.  Peer review of grant applications: what do we know? , 1998, The Lancet.